Cargando…

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression

The purpose of the study was to assess the prognosis of HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression and investigate the predictors of complete response. HER2-positive metastatic breast cancer patients who received long-term trastuzumab were included in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dogan, Izzet, Aydin, Esra, Khanmammadov, Nijat, Paksoy, Nail, Saip, Pinar, Aydiner, Adnan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232540/ https://www.ncbi.nlm.nih.gov/pubmed/37258548 http://dx.doi.org/10.1038/s41598-023-35715-2

Ejemplares similares

Efficacy and outcomes of systemic chemotherapy in posttransplant and immunosuppression associated Kaposi sarcoma: Twenty years experience of a tertiary cancer center
por: Khanmammadov, Nij̇at, et al.
Publicado: (2023)

Toxicity management and efficacy of carboplatin desensitization therapy for recurrent epithelial ovarian carcinoma: A real-world study
por: Paksoy, Nail, et al.
Publicado: (2022)

Weekly paclitaxel treatment in the first-line therapy of classic Kaposi sarcoma: A real-life study
por: Paksoy, Nail, et al.
Publicado: (2023)

Evaluation of clinicopathological features determining treatment response in patients with ALK mutant NSCLC
por: Dogan, Izzet, et al.
Publicado: (2022)

High-dose chemotherapy followed by autologous stem cell transplantation for adult patients With first relapse of Ewing’s sarcoma: A single institution experience
por: Paksoy, Nail, et al.
Publicado: (2022)

Trastuzumab beyond progression in HER2‐positive metastatic breast cancer
por: Al‐Naqqash, Manwar, et al.
Publicado: (2021)

Targeting HER2 in breast cancer: beyond trastuzumab
por: Winer, EP
Publicado: (2011)

Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
por: Tsang, R Y, et al.
Publicado: (2012)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients
por: Cheng, Y C, et al.
Publicado: (2010)

Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment
por: Park, Y H, et al.
Publicado: (2014)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

Infused Therapy and Survival in Older Patients Diagnosed with Metastatic Breast Cancer who Received Trastuzumab
por: Griffiths, Robert I, et al.
Publicado: (2011)

Trastuzumab Blocks the Receiver Function of HER2 Leading to the Population Shifts of HER2-Containing Homodimers and Heterodimers
por: Zhao, Jun, et al.
Publicado: (2021)

Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer
por: Callahan, Rena
Publicado: (2014)

Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin(®)) in patients with HER2-positive metastatic breast cancer
por: Chen, Xiaoying, et al.
Publicado: (2019)

Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer
por: Levicki, Rea, et al.
Publicado: (2023)

Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer
por: Lammers, Philip E., et al.
Publicado: (2018)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Veeraraghavan, Jamunarani, et al.
Publicado: (2021)

HER2 therapy: Molecular mechanisms of trastuzumab resistance
por: Nahta, Rita, et al.
Publicado: (2006)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
por: Rudkouskaya, Alena, et al.
Publicado: (2020)

Trastuzumab beyond progression in HER2-positive advanced breast cancer: The Royal Marsden experience
por: Waddell, T, et al.
Publicado: (2011)

Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group
por: Dogan, Izzet, et al.
Publicado: (2023)

The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study
por: Dogan, Izzet, et al.
Publicado: (2022)

Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006–2014)
por: Daniels, Benjamin, et al.
Publicado: (2018)

Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab
por: Kim, In-Ho, et al.
Publicado: (2017)

Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab
por: Wang, Lize, et al.
Publicado: (2021)

Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin(®)) in patients with HER2‑positive metastatic breast cancer
por: Chen, Xiaoying, et al.
Publicado: (2019)

Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis
por: Han, Yiqun, et al.
Publicado: (2019)

Trastuzumab-based regimens beyond progression: A crucial treatment option for HER2+ advanced/metastatic breast cancer
por: Sanglier, Thibaut, et al.
Publicado: (2022)

Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations
por: Jeyakumar, Alwin, et al.
Publicado: (2012)

Maintenance Therapy with Trastuzumab in Her2 Positive Metastatic Parotid Ductal Adenocarcinoma
por: Iqbal, Muhammad Shahid, et al.
Publicado: (2014)

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
por: de Oliveira Taveira, Mateus, et al.
Publicado: (2017)

Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance
por: Upton, Rosalynd, et al.
Publicado: (2021)

Safety survey on infusion reaction and cardiac dysfunction when switching from reference trastuzumab (HERCEPTIN(®)) to biosimilar trastuzumab (Trastuzumab‑NK) in the treatment of HER2‑positive breast cancer
por: Abe, Tomoya, et al.
Publicado: (2023)

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2021)

Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study
por: Li, Feng, et al.
Publicado: (2021)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019)

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer
por: Palmieri, Carlo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gi6pkr0nfibvegeuk8rr4v40nj